Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction;Kemoterapi til patienter med metastatisk karcinom i øsofagus og den gastroøsofageale overgang -En gennemgang af et Cochrane-review

Ugeskrift for Laeger

Volumn 170, Issue 8, 2008, Pages 633-636

  Vestermark, Lene Weber ^a   Sørensen, Peter ^a   Pfeiffer, Per ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

COMPARATIVE STUDY; ESOPHAGUS TUMOR; EVIDENCE BASED MEDICINE; HUMAN; LOWER ESOPHAGUS SPHINCTER; METASTASIS; MORTALITY; PALLIATIVE THERAPY; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; EVIDENCE-BASED MEDICINE; HUMANS; PALLIATIVE CARE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 41449104359     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Sem Radiat Oncol 2007;17:38-44.
2. Homs MY, von der Gaast A, Siersema PD et al. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev. 2006 Oct; (4): CD004063. Review.
3. Chau I, Norman AR, Cunningham D et al. Is there a differential chemotherapy effect in patients with locally advanced or metastatic oesophageal (O), oesophago-gastric junction (OGJ), and gastric (G) adenocarcinoma? A pooled analysis of four randomised controlled trials (RCTs). ASCO GI 2007:abstract 75.
4. Wagner AD, GrotheW, Haerting J et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9.
5. Wagner AD, Grothe W, Behl S et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews 2005, Issue 2.
6. Cunningham D, Rao S, Starling T et al. Randomized multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced esophagogastric cancer: The REAL 2 trial. J Clin Oncol 2006;24(18S): abstr LBA4017.
7. Dupont J, Jensen HA, Jensen BV et al. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer. Acta Oncol 2007;46:330-5.
8. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III Study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-7.
9. Van Meerten E, van der Gaast A. Systemic treatment for oesophageal cancer. Eur J Cancer 2005;41:664-72.
10. Victorson D, Soni M, Cella D. Metaanalysis of the correlation between radiographic tumor response and the patient-reported outcomes. Cancer 2006;106:494-504.